TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
In This Article:
EDINBURGH, Scotland, Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today provides an update to its shareholders and highlighted the Company's operational achievements thus far in 2024.
"The Company has made tremendous strides during the current year and bolstered its standing as a leading clinical-stage biopharmaceutical company," said Bryan Kobel, CEO of TC BioPharm. "The ACHIEVE UK trial has progressed with alacrity since we received MHRA acceptance of the increased dosing regimen; 8 patients have been dosed to date, including 2 patients that have received their 4th and final dose, all patients are in Cohort A bringing the total patients dosed to xx. We recently announced a new site opening, Guy's and St. Thomas Hospital which is one of the leading oncology clinics in the UK, this is expansion is related to increased scope and interest in the trial. Another site has opened since this announcement, and we are working towards opening two more sites in Q1 2025. Additionally, our compassionate use program has received physician attention in the UK and US, informing us of TCB008's potentially broad use case in patients suffering in various forms of cancer."
In addition to its existing therapeutic platform, TC BioPharm has signed two separate non-binding LOIs for acquisitions in cell therapy modalities outside the core of TCB008, announced its intention to begin proof of concept for preclinical trials for the treatment of Mpox with a leading infectious disease expert in the UK, and formed a strategic partnership with a leading University for AI initiative in the potentially multi-billion dollar field of donor screening for allogeneic cell therapies. In Q1 2024, cash burn was reduced by 50%, and TCBP aligned R&D efforts towards commercial applications. The benefits of these measures are now evident in Q4 2024, including Dr. Lauren Bor's team expects to implement manufacturing process improvements months ahead of the announced 24-month schedule. Directly correlated to our achievements of our strategic initiatives and milestone successes, the Company added approximately $8 million in capital to the balance sheet in August in a non-brokered transaction with an investor group."
First Half 2024 Highlights
-
Announced that the MHRA has officially accepted its proposed amendment to the Company's clinical trial authorization (CTA).
-
The amendment allows for an increase in dosing size of TCB008 (unmodified expanded gamma delta T cell Lymphocytes), up to 230 million gamma delta T-cells per dose.
-
-
Completed the dosing of 5 new patients in the ACHIEVE Phase 2b trial ongoing in the UK.
-
To date, the trial has successfully dosed 8 patients with their first and second doses, of a possible 4 doses at the higher dose level.
-
-
TCBP Announced the Launch of the Compassionate Use Program for TCB008.
-
TC BioPharm Announced Execution of Two Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies and NK Platform Technologies.
-
Developed a streamlined and scaled-up manufacturing process
-
increases treatment capacity from 52 patient treatments per year to more than 1,000
-
Cost reduction of 85% per patient treatment.
-